Oncology & Cancer

'Double decker' antibody technology fights cancer

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have created a new class of antibody-drug conjugates (ADCs), using a versatile "double decker" technology that ties antibodies and a drug together ...

Oncology & Cancer

Inhibitors support immune therapy for leukemia

New immune therapies are considered a promising lead for treating recurring acute myeloid leukemia (AML). Antibodies are able to eliminate even those cancer cells that cannot be removed via regular therapies. Scientists from ...

Oncology & Cancer

Single-dose PCV13 immunogenic, safe in pediatric oncology

(HealthDay)—For pediatric and adolescent oncology patients, a single-dose 13-valent pneumococcal conjugate vaccine (PCV13) is safe and immunogenic, according to a study published online July 11 in Cancer.

Medical research

New approach makes cells resistant to HIV

Scientists at The Scripps Research Institute (TSRI) have found a way to tether HIV-fighting antibodies to immune cells, creating a cell population resistant to the virus. Their experiments under lab conditions show that these ...

Oncology & Cancer

Antibody is effective against radiation-induced pulmonary fibrosis

Radiation therapy is part of the treatment regimen for about two thirds of cancer patients today. Radiotherapy is well tolerated in most cases, but it can also lead to damage in healthy tissues that are also irradiated. One ...

page 11 from 16